Fondation IPSEN, Nature Medicine and Nature Immunology present:

Multiple Sclerosis: From Pathogenesis to Therapy

June 6, 2008

Espace Charles Louis Havas, Paris, France

This mini-symposium will address open questions in multiple sclerosis
research, with the goal of identifying future directions that may lead
to therapy.

Application Deadline: March 31, 2008

Attendance at this meeting is free on acceptance of application. To
apply and for more information visit:
www.nature.com/natureconferences/eandc/MS

Hello everybody,

I have a question on how to blank the results from a typical double
sandwich ELISA assay. The assay measures therapeutic antibody in
human serum and I have two blanks available : assay buffer and
calibrator "Zero" containing 0.05%% of human serum (after MRD 1:2000)
and no analyte.

So far I was blanking all results only with the assay buffer value. Is
this totally incorrect? I was assuming that calibrator "Zero" should be
part of the calibration curve.

If standard "Zero" should be used as a blank, then how to construct
the standard curve in the 4PL model? It would mean that standard zero is
not included in the model. Would this be a correct approach?

Thank you for your help in this educational exercise

t

QC Officer,

Investigational Drug Program

BC Cancer Agency

phone: 604-675-8000, ext 7026

fax: 604-675-8183

Hi,
Recently, I am involved in nonspecific stimulation of
Jurkat T cells with 10 ng/ml of PMA and 1 µM of
Ionomycin. After 4 hours of incubation in CO2
incubator shows a decline in cell number. After 24
hours of incubation, I noticed a cell death up to 60%%
and IL-2 assay production was up to 90 pg/106 cells.
I would be happy, if some of suggest me, whether, I
should find increase in cell number along with the
IL-2 production.
I am looking forward for your valuable suggestions.
Thank you for your understanding.
With regards
Jayaseelan

____________________________________________________________________________________
Be a better friend, newshound, and
know-it-all with Yahoo! Mobile. Try it now. http://mobile.yahoo.com/;_ylt=Ahu06i62sR8HDtDypao8Wcj9tAcJ

I've recently tried a PE-conjugated anti human PD-1 antibody, to stain
some human PBMCs in inflammatory and autoimmune conditions.

Some published papers use a FITC-conjugated antibody, same clone as
mine (MIH4), but the graphs for their staining show an increased
signal compared to mine.

Could it be possible that the PE conjugation affects the binding of
the antibody, reducing its specificity compared to FITC?

Waiting for some replies...

Thanks in advance :-)

AR

ultimate biological latest projects, and news and articles free to
read

http://xrl.us/bf8th